Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Diabetic Retinopathy, Diabetic Blindness
Interventions: Patient Navigation; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Interventions: Melphalan, Carboplatin, Etoposide, Vincristine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Months to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Radiation Retinopathy
Interventions: ranibizumab 2.0 mg; Drug
Lead sponsor: The New York Eye Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Degeneration, Retinal Vein Occlusion
Interventions: Triamcinolone Acetonide (TAC-PF); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease
Interventions: intraocular injection guide, standard lid speculum; Device
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Von Hippel-Lindau Syndrome
Interventions: Ranibizumab, E10030; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Age Related Macular Degeneration
Interventions: Intravitreal Aflibercept injection; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: St Louis, Missouri • McAllen, Texas

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: Melatonin, Placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Retina Center, Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions: High Dose NT-501 implant, Low Dose NT-501 implant, Sham; Combination Product · Other
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more

Conditions: Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions: Photobiomodulation, Ketogenic diet; Behavioral
Lead sponsor: Bristlecone Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Macular Degeneration
Interventions: Pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Retinal Detachment Rhegmatogenous
Interventions: Intravitreal 100% C3F8 Injection, Pars plana vitrectomy or pars plana vitrectomy with scleral buckle; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Retinoschisis, X-Linked
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab; Drug
Lead sponsor: Ohr Pharmaceutical Inc.; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more

Conditions: Retinitis Pigmentosa
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Exudative Age Related Macular Degeneration
Interventions: Ranibizumab Injection [Lucentis]; Drug
Lead sponsor: Southeast Clinical Research Associates, LLC; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Charlotte, North Carolina • Statesville, North Carolina

Conditions: Atrophy, Geographic
Interventions: GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Glaucoma, Retinal Disease, Corneal Disease
Interventions: Nidek Mirante, Optovue RTVue XR Avanti, Optos P200DTx; Device
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 22 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Interventions: Ocufolin; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Age-related Macular Degeneration
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more

Conditions: Macular Degeneration
Interventions: rhuFab V2 (ranibizumab); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 70
States / cities: Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more

Conditions: Retinoblastoma, Cataracts Infantile, Glaucoma, Congenital, Leucocoria
Interventions: CRADLE, Red reflex testing; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 7 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Patient Navigator Intervention for Diabetic Retinopathy

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

Assessment of Novel Intraocular Injection Guide

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

OCT Biomarkers for Diabetic Retinopathy

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Sleep, Diabetic Retinopathy and Melatonin

ERG/EOG Study in AMD Patients Treated With Ranibizumab

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Use of Preoperative Gas in Eyes With Macula-off Rhegmatogenous Retinal Detachment (RRD)

Mothers Experiences With X-linked Retinoschisis Compared to Fathers Experiences

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Oral N-acetylcysteine for Retinitis Pigmentosa

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

Agreement and Precision Study of the Nidek Mirante

Clinical Applications of Advanced Ophthalmic Imaging

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma